Robert McWilliams

1 month ago | nature.com | Jacob J. Orme |Robert McWilliams |Robert Mcwilliams |Matthew Block |Aaron Mansfield |Svetomir N. Markovic | +3 more

AbstractImmune checkpoint inhibitors (ICI) are effective for advanced melanoma. However, most develop ICI resistance. Tumor-derived soluble PD-L1 (sPD-L1) and other immunosuppressive factors drive resistance. We hypothesized that therapeutic plasma exchange (TPE) may remove sPD-L1 from circulation and overcome ICI resistance. Patients with metastatic ICI-resistant melanoma and elevated sPD-L1 received radiotherapy to a minority of metastatic lesions, TPE, and ICI re-challenge.

Feb 16, 2024 | nature.com | Eric P Grewal |jun chen |Robert McWilliams |Robert Mcwilliams |Lu Yang |Evidio Domingo-Musibay | +5 more

AbstractBoth targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of targeted and immunotherapy given prior to therapeutic lymph node dissection (TLND) would be tolerable and drive robust pathologic responses.